Results 161 to 170 of about 39,319 (333)
PI3Kδ Inhibitor Parsaclisib in Japanese Patients With Relapsed or Refractory Follicular Lymphoma
CITADEL‐213 evaluated the efficacy and safety of parsaclisib (PI3Kδ inhibitor) in Japanese patients with relapsed or refractory follicular lymphoma (R/R FL). The objective response rate was 88.1%, with 23.8% of patients experiencing a complete response and 64.3% experiencing a partial response; treatment‐emergent adverse events led to parsaclisib ...
Noriko Fukuhara+15 more
wiley +1 more source
Introduction: Patients with mantle cell lymphoma (MCL) frequently develop resistance to ibrutinib. Lymphoma-associated macrophages (LAMs) may play a causal role in this resistance but remain underexplored in current literature.
Xiaoqing Sun+10 more
doaj
BTK inhibitor ibrutinib in CLL and mantle cell lymphoma [PDF]
Jame Abraham, Matt Stenger
openalex +1 more source
Purpose We evaluated the safety and feasibility of anti-CD19 chimeric antigen receptor-modified T (CAR-T) cell therapy in patients with chronic lymphocytic leukemia (CLL) who had previously received ibrutinib.
C. Turtle+11 more
semanticscholar +1 more source
Our study reveals that hypoxia inhibitors ameliorate iodine uptake dysfunction in thyroid cancer by acting on the hsa_circ_0023990/miR‐448/DNMT1/NIS signaling pathway. ABSTRACT This research seeks to investigate how hypoxia inhibitors enhance iodine uptake in thyroid cancer cells. Clinical samples were gathered and assessed for hsa_circ_0023990, DNMT1,
Ruiqin Gou+5 more
wiley +1 more source
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
BACKGROUND Bruton's tyrosine kinase (BTK) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers. In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's
Michael L. Wang+30 more
semanticscholar +1 more source
In the tumor microenvironment, selinexor suppresses tumor cell growth and prevents macrophages from polarizing to M2 populations. The lower concentration of selinexor decreases CAR‐T cell exhaustion, enhances its cytotoxicity, and upregulates NGFR expression to prompt CAR‐T cell proliferation.
Wenjing Luo+9 more
wiley +1 more source
Ibrutinib Resistance in Chronic Lymphocytic Leukemia [PDF]
Gustaaf Reurink+7 more
openalex +1 more source
Lung cancer development involves mechanisms like reduced EGFR/EGF ubiquitination driving cancer cell behaviors and immune evasion via loss of PD‐1/PD‐L1 ubiquitination. Balancing ubiquitination and deubiquitination may be a potential therapeutic strategy. ABSTRACT Non‐small cell lung cancer (NSCLC) remains a leading cause of cancer mortality.
Guangyao Zhou+5 more
wiley +1 more source
Classification of Platelet‐Activating Anti‐Platelet Factor 4 Disorders
ABSTRACT Introduction The prototypic anti‐platelet factor 4 (PF4) disorder—heparin‐induced thrombocytopenia and thrombosis (HITT)—features immunoglobulin G (IgG) class antibodies that activate platelets, monocytes, and neutrophils in a mainly heparin‐dependent fashion via Fcγ receptor‐dependent cellular activation.
Theodore E. Warkentin
wiley +1 more source